Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Drug Company Buyout to Boost Development of Liver Disease Drugs

By LabMedica International staff writers
Posted on 20 Apr 2016
A strategic buyout will broaden the role of an American pharmaceutical research and manufacturing company in the area of liver diseases.
 
 
 
The biopharmaceutical company Gilead Sciences (Foster City, CA, USA) has announced the purchase of Nimbus Apollo Inc., a subsidiary of Nimbus Therapeutics LLC (Cambridge, MA, USA). More...
Gilead is set to pay 400 million USD for Nimbus Apollo, and the parent company could receive up to another 800 million USD, if Nimbus Apollo's drug development program meets certain milestones in testing results and medicine approval and sales.
 
 
 
Implementation of the agreement will give Gilead access to the experimental drug NDI-010976, which is being tested for the treatment of non-alcoholic steatohepatitis, known by the acronym NASH. This disorder causes inflammation, cell damage, progressive scarring, and cirrhosis of the liver. An estimated 15 million Americans suffer from NASH.
 
 
 
In February 2016, the drug NDI-010976 was awarded [US] Food and Drug Administration "fast-track" designation, which speeds up regulatory review and approval. The drug blocks two forms of the enzyme acetyl CoA carboxylase (ACC), which is involved in cellular fatty acid metabolism.
 
 
 
Dr. Norbert Bischofberger, CSO at Gilead, said, "The acquisition will complement and further strengthen Gilead's ongoing efforts to address unmet needs in NASH."
 
 
 
In addition to the acquisition of NDI-010976, the purchase brings to Gilead Nimbus' breakthrough computational chemistry platform that was designed to enable rapid discovery, design, and tweaking of potential medicinal compounds.
 
 
Related Links: 
 
 


 

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.